With the advent of dozens of AD genes emerging from GWAS that implicate immune cells, e.g., microglia and innate immune mechanisms, novel therapeutics aimed at attenuating neuroinflammation have entered into clinical trials, e.g., targeting CD33 and TREM2 [3]. Here, TREM2 is linked to Alzheimer disease.